Ravinder Wali, MD
Nephrology · Worcester, MANPI 1821030933
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $268 of the $312 with a category attached, or 85.7%. 5 manufacturers reported payments, led by Veloxis Pharmaceuticals, Inc. at 34.5% of the total. Reporting peaked in 2021 at $110 and has fallen 59.4% since, to $45 in 2023. That places this record below the midpoint for nephrology clinicians in MA, where the typical reported total is $287.
Across 13 payments — averaging $24.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veloxis Pharmaceuticals, Inc.$108
- Mallinckrodt Hospital Products Inc.$67
- Vifor Pharma, Inc.$67
- E.r. Squibb & Sons, L.L.C.$53
- Astellas Pharma US Inc$18
What the payments were for
- Food & beverage$26886%
- Education$4514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veloxis Pharmaceuticals, Inc. | 5 | $108 |
| Mallinckrodt Hospital Products Inc. | 2 | $67 |
| Vifor Pharma, Inc. | 2 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| Astellas Pharma US Inc | 1 | $18 |
How this compares
$312 in reported general payments places this provider in the 50th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 96 | $65,142 |
| EliquisApixaban | 20 | $11,351 |
| Valganciclovir Hcl | 65 | $10,301 |
| Cinacalcet Hcl | 58 | $2,745 |
| Tacrolimus | 45 | $2,478 |
| Febuxostat | 19 | $2,021 |
| Labetalol Hcl | 40 | $1,904 |
| Mycophenolate Mofetil | 41 | $1,123 |
| Pantoprazole Sodium | 137 | $1,016 |
| Famotidine | 57 | $857 |
| Atorvastatin Calcium | 134 | $837 |
| Cefpodoxime Proxetil | 15 | $820 |
| Prednisone | 142 | $812 |
| Terazosin Hcl | 25 | $754 |
| Carvedilol | 88 | $703 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Worcester
- Anil ChandrakerWorcester$162K
- Matthew TrainorWorcester$26K
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Michael GermainSpringfield$443K
- Rekha AbichandaniCambridge$442K
- Leslie FangBoston$388K
- Nicolaos AthienitesBrockton$294K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.